New Releases from NCBI BookshelfPembrolizumab (breast cancer, triple-negative, neoadjuvant and adjuvant): Benefit assessment according to §35a SGB V (expiry of the decision): IQWiG Reports – Commission No. A24-104 [Internet].​Pembrolizumab (breast cancer, triple-negative, neoadjuvant and adjuvant): Benefit assessment according to §35a SGB V (expiry of the decision): IQWiG Reports – Commission No. A24-104 [Internet].